PapersPMID:17875243
Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
melatoninWhat moved
1 findingHow to read these marks →- Decreases sleep onset latency
very limitedreplicated ×11
“A significant and clinically relevant shortening of sleep latency to the same extent as most frequently used sleep medications was also found (-24.3 vs.-12.9 minutes; p = 0.028).”
- Study
- RCT
- Duration
- 3 weeks
- Dose studied
- prolonged-release melatonin (Circadin) 2 mg once daily, 2 h before bedtime
- Population
- Adults aged 55-80 years with primary insomnia
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults aged 55-80 years with primary insomnia
- Participants
- 354
- Comparator
- placebo
- Duration
- 21 days
- Endpoints measured
- 3